Kristian Windfeld

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

Johann S. de Bono, Nicole Concin, David S. Hong et al. · The Lancet Oncology · 2019 · 217 citations · Full text

Innovatv 201, Tisotumab Vedotin, Medicine +10

Safety and efficacy of idalopirdine, a 5-HT 6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial

David Wilkinson, Kristian Windfeld, Eskild Colding‐Jørgensen · The Lancet Neurology · 2014 · 159 citations

Placebo-controlled Phase 2, Neurodegenerative Diseases, Alzheimer's Disease +13

Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease

Alireza Atri, Lutz Frölich, Clive Ballard et al. · JAMA · 2018 · 159 citations · Full text

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

David S. Hong, Nicole Concin, Ignace Vergote et al. · Clinical Cancer Research · 2019 · 122 citations · Full text

A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.

P. Damsbo, Per Clauson, Thomas Marbury et al. · Diabetes Care · 1999 · 119 citations